Interestingly, from the three MBP peptides only GH17 increased IL-10 production in PBMCs regardless of their origin; the level of IL-10 in GH17-treated PBMCs from HD was two times higher than those in cells from MS patients. This evidence concerns the gene MBP and Huntington disease.